Funding award for bladder cancer research

Professor Jim Catto (Oncology & Metabolism)  along with Dr Sarah Danson,  researchers from Glasgow University and Sitka Bioscience in Vancouver have received funding from the New Agents Committee (part of Cancer Research UK)  for INSTIL: INvestigation of STK-01 as intra-vesical treatment for bladder cancer.

STK-01 is a novel 5-10nm molecule developed to increase retention, uptake and penetration of drugs on mucosal surfaces. STK-01 consists of a docetaxel (DTX; the same API that is contained in commercially available Taxotere®) surrounded by hyperbranched polyglycerol (HPG; glycerol scaffold, muco-adhesive primary amine, hydrophilic and hydrophobic drug carrier and solubility components). Animal studies have shown that STK-01 increases DTX penetration into the bladder wall and resultant tissue concentrations when compared to plain doectaxel.

The first in human evaluation of STK-01 will be conducted, determining the optimal dose and schedule using patients prior to bladder removal. They hope to develop a novel agent with huge ponytail for this disease.